J Immunother Cancer
Biomarkers; Cancer immunotherapy; Checkpoint inhibitor; PD-1/PD-L1
Identification of biomarkers in cancer immunotherapy that predict therapeutic response and/or limit adverse events are a critical need in the field. To address recent progress and hurdles around cancer biomarker development and utilization, the Society for Immunotherapy of Cancer (SITC) convened a workshop, "Immuno-Oncology Biomarkers: State of the Art," on May 16-17, 2018. Topics discussed included challenges in handling biospecimens, identification and validation of new biomarkers, data sharing, and collaborating across disciplines to advance biomarker development. Panel discussions followed session presentations to help foster participant conversation and discuss future projects and collaborations. The results of the Workshop include the development of new initiatives for the SITC Biomarkers Committee.
Earle A. Chiles Research Institute
Butterfield, Lisa H; Disis, Mary L; Fox, Bernard A; Kaufman, David R; Khleif, Samir N; and Wang, Ena, "SITC 2018 workshop report: Immuno-Oncology Biomarkers: State of the Art." (2018). Articles, Abstracts, and Reports. 998.